• Mashup Score: 3

    Nature – The FDA’s accelerated-approval process was designed to help people access life-saving drugs. But gaps in communication could mean that people are undergoing treatments known to be…

    Tweet Tweets with this article
    • Fantastic, nuanced article by @smjyoti @Nature on @US_FDA Accelerated Approval Program, ft. our @JAMAOnc work on exposure to withdrawn drugs. Stay tuned for work w/ @Ron_cology @RhubbBstat @SteveJoffe @Arnold_Ventures to inform next gen of program https://t.co/bIWIw67DAR

  • Mashup Score: 2

    Ravi B. Parikh, MD, MPP, explores the growing burden of prior authorization, why it’s happening, and how we can start to fix it from the inside.

    Tweet Tweets with this article
    • Daily, I see posts from doctors railing on #insurance co. abt prior auth. But when payers are only agent incentivized to lower costs, prior auth results. Let's not shout at the wind; instead put teeth behind cost-conscious care efforts. My latest @Medscape https://t.co/fq4IyvRAUH https://t.co/iGUOZzNrXY

  • Mashup Score: 1

    Clinical guidelines have endorsed early palliative care for patients with advanced malignancies, but receipt remains low in the US. This study examined the association between Medicaid expansion under the Affordable Care Act and receipt of palliative care among patients newly diagnosed with advanced-stage cancers. Using the National Cancer Database, we found that the percentage of eligible patients who received palliative care as part of first-course treatment increased from 17.0 percent preexpansion to 18.9 percent postexpansion in Medicaid expansion states and from 15.7 percent to 16.7 percent, respectively, in nonexpansion states, resulting in a net increase of 1.3 percentage points in expansion states in adjusted analyses. Increases in receipt of palliative care associated with Medicaid expansion were largest for patients with advanced pancreatic, colorectal, lung, and oral cavity and pharynx cancers and non-Hodgkin lymphoma. Our findings suggest that increasing Medicaid coverage f

    Tweet Tweets with this article
    • RT @HACLab_UPenn: New publication from @ravi_b_parikh and colleagues in @Health_Affairs https://t.co/i0xehOWrPq

  • Mashup Score: 0

    In this discussion, Alicia Morgans interviews Ravi Parikh about his session on interventions to prevent or mitigate frailty in prostate cancer patients. Parikh emphasizes the necessity of screening for frailty and tailoring treatment strategies for older patients who may experience different side effects. He elaborates on strategies such as prehabilitation before prostate cancer surgery and…

    Tweet Tweets with this article
    • Check out this @urotoday conversation with @CaPsurvivorship on Frailty, Bone Health, and Cardiovascular Screening in #prostatecancer! Hopefully some useful tips for practice. #pcsm @PCFnews @johnlin08 @ChristinaDieli https://t.co/8OvuI4rmVT

  • Mashup Score: 1

    This has been on the minds of the Food and Drug Administration (FDA), as it has released several pieces of guidance for using AI in areas such as drug development and software as a medical device over the past 5 years.   The intention of these documents is to try to stay ahead of the rapid expansion of AI into clinical care. Over 500 AI and machine learning devices have been cleared by the FDA –…

    Tweet Tweets with this article
    • Check out our latest @HACLab_UPenn blog post - how is #ArtificialIntelligence regulated in #healthcare “, and how should it be? https://t.co/tgGzlJlWd2 https://t.co/lcBsVyCfSo

  • Mashup Score: 3

    The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.

    Tweet Tweets with this article
    • Calling all medical oncologists who treat lung cancer: Help us learn about prognostic decision aids as part of a @NIH-funded study. Complete this 15 min survey - https://t.co/iaFtU1Mwbt. We offer an incentive as a thank you. #LCSM #MedTwitter #OncTwitter. Please share! #ASCO23